去年，ImmuCell Corp表现最佳的业务板块First Defense® product line实现营收27.45M美元。United States的营收贡献最高，去年达到24.39M美元。最近一个季度，截至2026-06-30，ImmuCell Corp表现最佳的业务板块First Defense® product line实现营收7.11M美元。United States的营收贡献最高，达到6.23M美元。

业务

营业收入

占比

年报

年报

单季报

First Defense® product line

Other animal health

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

First Defense® product line

27.45M(99.29%)

26.31M(99.32%)

17.29M(98.98%)

18.41M(99.16%)

18.93M(98.39%)

15.07M(98.24%)

13.24M(96.51%)

Other animal health

196.39K(0.71%)

178.92K(0.68%)

177.74K(1.02%)

156.01K(0.84%)

309.88K(1.61%)

269.76K(1.76%)

344.88K(2.51%)

Other

--(--)

133.60K(0.97%)

地区

营业收入

占比

年报

年报

单季报

United States

Other

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

24.39M(88.23%)

22.89M(86.41%)

15.95M(91.29%)

17.02M(91.67%)

16.62M(86.37%)

13.64M(88.94%)

12.19M(88.84%)

Other

3.25M(11.77%)

3.60M(13.59%)

1.52M(8.71%)

1.55M(8.33%)

2.62M(13.63%)

1.70M(11.06%)

1.53M(11.16%)